4-(1H-pyrazol-1-yl)pyridine | 25700-13-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4-(1H-pyrazol-1-yl)pyridine
• 英文别名: 1-(pyridin-4-yl)-1H-pyrazole；4-pyrazol-1-ylpyridine
• CAS: 25700-13-4
• 化学式: C₈H₇N₃
• 分子量: 145.164
• InChiKey: BVQQFKCDQYLYFN-UHFFFAOYSA-N

物化性质

• 沸点：
  275.1±23.0 °C(Predicted)
• 密度：
  1.16±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  30.7
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-(1H-pyrazol-1-yl)pyridine 在 5%-palladium/activated carbon 、 氢气 作用下， 以 甲醇 为溶剂， 80.0 ℃ 、10.13 MPa 条件下， 反应 24.0h， 以83%的产率得到4-(1H-吡唑)-哌啶
  参考文献：
  名称：

  A Convenient Synthesis of (1H-Azol-1-yl)piperidines

  摘要：

  A convenient preparation of 3- and 4-(1H-azol-1-yl)piperidines by arylation of azoles (i.e., pyrazoles, imidazoles, and triazoles) with 3- and 4-bromopyridines and subsequent reduction of the pyridine ring was developed. The method was extended to benzo analogues of the title compounds.

  DOI：

  10.1055/s-0031-1291126
• 作为产物：
  描述：

  吡唑 、 4-溴吡啶 在 copper(l) iodide 、 N,N'-二甲基乙二胺 、 盐酸 、 sodium methylate 作用下， 以 N,N-二甲基甲酰胺 、 甲醇 、 水 为溶剂， 反应 12.5h， 以87%的产率得到4-(1H-pyrazol-1-yl)pyridine
  参考文献：
  名称：

  A Convenient Synthesis of (1H-Azol-1-yl)piperidines

  摘要：

  A convenient preparation of 3- and 4-(1H-azol-1-yl)piperidines by arylation of azoles (i.e., pyrazoles, imidazoles, and triazoles) with 3- and 4-bromopyridines and subsequent reduction of the pyridine ring was developed. The method was extended to benzo analogues of the title compounds.

  DOI：

  10.1055/s-0031-1291126

文献信息

• NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF
  申请人：FUJIFILM Corporation

  公开号：US20150322063A1

  公开（公告）日：2015-11-12

  A compound represented by Formula [1] (in the formula, Z 1 represents N, CH, or the like; X 1 represents NH or the like; R 1 represents a heteroaryl group or the like; each of R 2 , R 3 , and R 4 represents a hydrogen atom, a halogen atom, an alkoxy group, or the like; and R 5 represents a heteroaryl group or the like) or salt thereof.

  由式[1]表示的化合物（在该式中，Z表示N、CH或类似物；X表示NH或类似物；R表示杂环烷基或类似物；R2、R3和R4中的每一个表示氢原子、卤原子、烷氧基或类似物；R5表示杂环烷基或类似物）或其盐。
• N-aryl pyrazoles: DFT calculations of CH acidity and deprotonative metallation using a combination of lithium and zinc amides
  作者：Floris Chevallier、Yury S. Halauko、Christelle Pecceu、Ibrahim F. Nassar、To Uyen Dam、Thierry Roisnel、Vadim E. Matulis、Oleg A. Ivashkevich、Florence Mongin

  DOI：10.1039/c1ob05267e

  日期：——

  A series of N-aryl and N-heteroaryl pyrazoles have been deproto-metallated using a 2,2,6,6-tetramethylpiperidino-based mixed lithium–zinc combination. Mono-, di-, and tri-iodides have been obtained after subsequent trapping with iodine, depending on the substrate and on the quantity of base used. The results have been discussed in the light of the CH acidities of the substrates, determined both in the gas phase and in THF solution using the DFT B3LYP method.

  一系列N-芳基和N-杂芳基吡唑化合物通过基于2,2,6,6-四甲基哌啶的混合锂-锌试剂进行了去质子金属化反应。在随后与碘的捕获反应中，根据底物和所用碱的量的不同，分别得到了单碘、二碘和三碘化合物。研究结果根据底物的CH酸性进行了讨论，这些酸性在气相和THF溶液中均通过DFT B3LYP方法进行了测定。
• [EN] N1-(3,3,3-TRIFLUORO-2-HYDROXO-2-METHYLPROPIONYL)-PIPERIDINE DERIVATIVES AS INHIBITORS OF PYRUVATE DEHYDROGENASE KINASE<br/>[FR] DÉRIVÉS N1-(3,3,3-TRIFLUORO-2-HYDROXO-2-MÉTHYLPROPIONYL)-PIPÉRIDINE EN TANT QU'INHIBITEURS DE PYRUVATE DÉSHYDROGÉNASE KINASE
  申请人：MERCK PATENT GMBH

  公开号：WO2015090496A1

  公开（公告）日：2015-06-25

  Compounds of the formula (I) in which R, R1 and R3 have the meanings indicated in Claim 1, are inhibitors of pyruvate dehydrogenase kinase (PDHK), and can be employed, inter alia, for the treatment of diseases such as cancer.

  公式(I)中的化合物，其中R、R1和R3的含义如权利要求1所述，是丙酮酸脱氢酶激酶（PDHK）的抑制剂，可以用于治疗诸如癌症等疾病。
• α-d-Galacturonic Acid as Natural Ligand for Selective Copper-Catalyzed N-Arylation of N-Containing Heterocycles
  作者：Chunling Yuan、Yingdai Zhao、Li Zheng

  DOI：10.1055/s-0039-1690226

  日期：2019.12

  The first application of α-d-galacturonic acid hydrate (GalA) is reported here, as a potential O-donor ligand. The C–N couplings of N-heterocycles with aryl halides or arylboronic acids could be readily conducted and exhibited good functional group tolerance with characters of selectivity. These N-arylazoles allow rapid access to several pharmaceutical intermediates and can be easily transformed into a variety of other interesting scaffolds as well.

  这里报告了α-D-半乳糖醛酸水合物（GalA）作为潜在的O-供体配体的首次应用。N-杂环化合物与芳基卤化物或芳基硼酸的C-N偶联可以轻松进行，并且具有良好的官能团容忍性和选择性特征。这些N-芳基唑允许快速获得几种药用中间体，并且也可以轻松转化为各种其他有趣的骨架。
• [EN] PYRAZOLO [4, 3-D] PYRIMIDINES USEFUL AS KINASE INHIBITORS<br/>[FR] PYRAZOLO[4,3-D]PYRIMIDINES UTILES EN TANT QU'INHIBITEURS DE KINASES
  申请人：ORIGENIS GMBH

  公开号：WO2012143144A1

  公开（公告）日：2012-10-26

  The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.

  本发明涉及一种能够抑制一个或多个激酶，特别是SYK（脾酪氨酸激酶）、LRRK2（富含亮氨酸重复的激酶2）和/或MYLK（肌球蛋白轻链激酶）或其突变体的化合物的新颖化合物（I）的公式。这些化合物在治疗各种疾病中发挥作用。这些疾病包括自身免疫疾病、炎症性疾病、骨疾病、代谢性疾病、神经和神经退行性疾病、癌症、心血管疾病、过敏、哮喘、阿尔茨海默病、帕金森病、皮肤疾病、眼部疾病、传染病和与激素相关的疾病。